GLP1R and Obesity: Specifically, we hypothesize that based on the proposal adipocentric model with autonomic profiling, subtype-matched therapies (e.g., GLP-1 agonists for MUO, leucine supplementation with resistance training for sarcopenic obesity, cold exposure protocols for BAT deficit obesity) will help achieve greater reductions in cardiometabolic risk markers than standard (“one-size-fits-all approach”) at 12-month follow-up.